logo
Sign in

ATNX Stock Price, Chart, Stats & News

Athenex, Inc.
Save
2.33M
Market cap
Current P/E
Forward P/E

ATNX chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
25.97%
Operating margin
-68.02%
Pretax margin
-95.92%
Net margin
-96.26%
Effective tax rate
-0.35%
ROA
-48.50%
ROE
21.51%
D/E
-6.51x
Interest coverage ratio
-2.71x

ATNX valuation

P/E
P/S
0.02x
P/B
-0.20x
P/CF
-0.02x
P/FCF
-0.03x
P/OCF
-0.02x
PEG
-0.00x
EV multiple
0.06x

About

Athenex, Inc. is a biopharmaceutical company primarily dedicated to the discovery, advancement, and commercialization of therapeutic agents for oncological conditions. Its operations are structured across three distinct platforms: an Oncology Innovation Platform, a Global Supply Chain Platform, and a Commercial Platform. Among its leading product candidates is the Orascovery series, featuring oral paclitaxel combined with encequidar – an innovative oral formulation.

Similar securities

Based on sector and market capitalization

Report issue